Physician profile
Marta Bill
NPI 1710954946
$7,712.61
in general payments reported to CMS, 2019-2025
22 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,538 · 2022: $1,578 · 2023: $1,627 · 2024: $1,778 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,596.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,147.37 | 2021-2025 | Wegovy, Saxenda, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $983.14 | 2021 | |
| Amgen INC. | $982.31 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $827.19 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $711.37 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $591.92 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $406.56 | 2024-2025 | Voquezna |
| Pfizer INC. | $275.81 | 2023-2024 | |
| Abbott Laboratories | $273.90 | 2022-2024 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $263.97 | 2021-2022 | |
| Astellas Pharma US INC | $257.96 | 2024-2025 | Veozah |
| Dexcom, INC. | $229.25 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $165.47 | 2022 | |
| Corcept Therapeutics | $124.98 | 2025 | Korlym |
| Gilead Sciences, INC. | $107.37 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $95.25 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $94.51 | 2021-2024 | Gardasil 9, M-M-R II, Vaxneuvance |
| Hologic Sales and Service, LLC | $54.64 | 2022-2024 | Affirm Prone Biopsy System, Thinprep 2000 Processor |
| Sanofi-Aventis U.S. LLC | $45.42 | 2021-2022 | |
| Insulet Corporation | $31.89 | 2024 | Omnipod |
| Amarin Pharma, INC. | $23.03 | 2021 | |
| Averitas Pharma INC. | $19.30 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Bill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.